Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M …

Background: Osimertinib efficacy in pre-treated patients with epidermal growth factor
receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been …

The discovery of activating mutations in epidermal growth factor receptor (EGFR) in non-
small-cell lung cancer transformed the care and prognosis of patients and heralded the era …

Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer
(NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR …

Introduction Osimertinib resistance is inevitable. The purpose of this study was to explore the
predictive value of pretreatment clinical characteristics in T790M-positive non-small cell lung …

Background EGFR tyrosine kinase inhibitors (TKIs) have shifted the treatment paradigm in
advanced EGFR‐mutant non–small cell lung cancer (NSCLC). However, patients who are …

Introduction Osimertinib, a third-generation, irreversible, epidermal growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI), selectively inhibits both EGFR-TKI sensitizing (EGFRm) …

Introduction Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification
of on-target mechanisms of resistance (ie, EGFR C797S) to this third-generation EGFR …

The treatment of lung cancer has changed dramatically with the development of tyrosine
kinase inhibitors (TKIs) that target sensitizing somatic mutations of the epidermal growth …

9028 Background: Even though osimertinib (osi) is now the initial treatment for patients with
EGFR-mutant lung cancers, our knowledge about mechanisms of resistance (MOR) is …